The MMR status was known for 40 tumors, of which 34 (85%) were MMR-proficient and 6 (15%) were MMR-deficient with MLH1/PMS2 loss of staining and positive BRAF mutation, which associates with a sporadic tumor. This evidence concerns the gene MLH1 and neoplasm.